New UK study highlights HemoPill® acute as a triage tool for reducing inpatient gastroscopies

UK study on the HemoPill® acute shows that the bleeding-detection capsule could reduce the need for inpatient gastroscopies in patients with suspected non-variceal acute upper gastrointestinal bleeding (AUGIB)

Key findings

• 10 patients were given the HemoPill® acute. The HemoPill® acute showed a negative result in 6 and a positive result in 4 patients
• Adverse events occcurred in 0 cases and 90-day mortality was 0%
• HemoPill® as a triage tool led to a reduction of inpatient gastroscopies
• Patient with suspected non-variceal AUGIB and negative HemoPill® results could be safely managed as outpatients

Study details

• All patients included had been admitted to hospital with a suspected UGI bleed. The median Glasgow Blatchford Score was 9 and the median Rockall Score 4
• No pre-procedure fasting was required
• All patients with negative capsule results were managed as outpatients and  underwent urgent outpatient gastroscopy
• All patients with positive capsule results were managed as inpatients and underwent inpatient gastroscopy 

D'Cunha Kamath A, Friel JH, Braddy-Green C. Novel method for risk stratifying suspected acute non-variceal upper GI bleeds using a blood-detection capsule: first UK hospital experience. Frontline Gastroenterol. 2025; flgastro-2024-102883. Doi: 10.1136/flgastro-2024-102883.

For further clinical and product information, please follow our website links on the HemoPill® acute.

If you would like personal advice on our products, please do not hesitate to contact your local representative.